InvestorsHub Logo
Followers 25
Posts 2345
Boards Moderated 0
Alias Born 06/20/2020

Re: None

Wednesday, 07/06/2022 5:15:02 PM

Wednesday, July 06, 2022 5:15:02 PM

Post# of 42553
C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’ trial

https://thorax.bmj.com/content/early/2022/07/05/thoraxjnl-2022-218744